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Objective. To determine the frequency of mutations
(C282Y and H63D) in a newly identified gene HFE in
patients with hereditary haemochromatosis (HH) in
Sweden.
Design. Molecular genetic analyses of the HFE gene
(polymerase chain reaction (PCR) followed by
enzyme restriction) were performed in genomic DNA
from unrelated patients with a clinical diagnosis of
HH and in healthy subjects.
Settings. Patients with HH treated with phlebotomies
at Karolinska Hospital and Huddinge Hospital were
analyzed.
Subjects. Eighty-seven unrelated patients with HH
and 117 healthy controls.
Results. It was found that the HFE C282Y mutation
occurs in 94.2% of chromosomes from patients 
with HH. Eighty patients (92.0%) were homo-
zygous for the C282Y mutation and one was
heterozygous. Three patients were heterozygous for
both C282Y and H63D mutations. One patient 
was homozygous and one was heterozygous for 
the H63D mutation. One patient carried normal
alleles. In healthy controls, the C282Y mutation
occurred in nine subjects (7.7%), all of which 
were heterozygous. The H63D mutation was found 
in 28 control subjects, one of which was homo-
zygous.
Conclusions. We found that the majority of
patients with HH have the C282Y mutation in 
the HFE gene. The frequency of the H63D mu-
tation was higher in controls than in patients 
with HH, although in chromosomes at risk the
frequency of the H63D mutation was higher in
patients.
Keywords: genotype, haemochromatosis, HFE,
inherited disorders, iron.
Introduction
Hereditary haemochromatosis (HH) is considered to
be one of the most common autosomal recessive dis-
eases in white people [1]. HH is characterized by a
defect in the still unknown mechanism(s) regulating
iron absorption. As a result, patients with HH initially
accumulate iron in the plasma transferrin pool and
later in parenchymal organs, which may lead to
organ damage, such as liver cirrhosis, diabetes,
arthropathy, cardiac arrhythmias and hypogonadism.
Recently, a candidate gene for HH was cloned by
Feder et al. [2]. The gene is located on chromosome 6,
three megabases telomeric of the HLA region, and
has an organization and nucleotide sequence similar
to that of HLA class I genes. This gene is now called
HFE. The authors found two missense alterations in
the HFE gene. The most important mutation, which
results in a cysteine–tyrosine substitution at amino
acid 282 (C282Y), was present in 83% of the 178
patients tested. A second mutation, resulting in a his-
tidine–aspartate substitution at position 63 (H63D),
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was reported to be increased in patients with HH het-
erozygous for the C282Y mutation [2, 3].
Other studies in the USA [3, 4], Australia [5] and
France [6] confirmed that the C282Y mutation is pre-
sent in a high percentage of patients with HH. However,
the frequency of mutation varies somewhat between
these different reports. A group in Italy showed an even
lower incidence (69%) of the C282Y mutation in chro-
mosomes from patients with HH [7]. The objective of
the present study was to determine the presence of
these two mutations in patients with HH in Sweden.
Subjects and methods
Subjects
A total of 87 patients with HH were examined: 67
men with a mean age of 47 years (range 20–73
years) and 20 women with a mean age of 49 years
(range 25–72 years). The diagnostic criteria used
were high transferrin saturation (.60% in males and
.50% in females) and increased ferritin levels 
. 300 mg L21 (except in one 20-year-old patient) and
a liver biopsy with typical iron staining indicating pri-
mary haemochromatosis according to Scheuer et al.
[8]. All patients included in the study were, from a
clinical, biochemical and histopathological point of
view, homozygous [9]. Siblings to patients with HH in
the study were excluded. Patients were treated weekly
with phlebotomies of 450 mL (1 L of blood contains
approximately 0.5 g of iron). Patients with other
causes of iron overload, such as excessive intake of
oral supplementation, were excluded and none had
received more than two units of blood from transfu-
sions. Alcohol consumption was less than 30 g per
day in all patients except one, who consumed 60 g of
alcohol per day. All patients were negative for anti-
bodies to hepatitis C, tested using the recombinant
immunoblot assay II (Chiron Corporation, Emeryville,
CA, USA). Of the male patients with 5 g or less of iron
stores (n 5 11), one was a blood donor and one had
ulcerative colitis. No explanation was available for the
other subjects with little iron. DNA from 117 random
healthy Swedish subjects was used as controls. The
individual identity of these samples was not known.
Methods
Genomic DNA was isolated from blood using the
QIAamp Blood Kit (QIAGEN, Germany). Two por-
tions of the HFE gene surrounding both mutations
were amplified separately using the polymerase chain
reaction (PCR) with HFE specific primers (for the
C282Y mutation, forward primer: 59- GTG ACC TCT
TCA GTG ACC and reverse primer: 59- AAT GAG GGG
CTG ATC CAG; for the H63D mutation, forward
primer: 59-ATG GGT GCC TCA GAG CAG and reverse
primer: 59- AGT CCA GAA GTC AAC AGT). PCR was
performed using the GeneAmp PCR system 9600
(Perkin-Elmer, Norwalk, CT, USA) in a final volume of
100 mL. The PCR mixture contained 1 3 buffer (10
mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl, pH 8.3),
0.2 mM of each dNTP, 0.3 mM of each primer, 2.5U
of Taq DNA polymerase (Boehringer Mannheim,
Germany) and 80–100 ng of DNA. PCR was carried
out for 35 cycles (annealing at 628C and 508C for the
C282Y and H63D mutation, respectively. The ampli-
fied products (10 mL) were digested with Sna BI
(BioLabs, New England, MA, USA) for the C282Y
mutation or with Bcl I (BioLabs) for the H63D muta-
tion, according to the manufacturer9s recommenda-
tions. The digested products were then run on a 4%
NuSieve 3:1 agarose (FMC BioProducts – Europe,
Denmark) gel at 100 V for 1.5 h and photographed
under UV light. The C282Y mutation creates a Sna BI
restriction site. Thus, the 237-bp PCR reaction prod-
uct digested with Sna BI shows two fragments of 197
and 40 bp in mutant DNA. In normal DNA, no Sna BI
site is created and, therefore, only one fragment cor-
responding to the 237-bp PCR product is visible in
the gel (Fig. 1a). The H63D mutation removes the Bcl
I site in the 210-bp PCR product, while in normal
DNA Bcl I digestion results in two fragments of 129
and 81 bp (Fig. 1b).
Statistic analyses
The statistical significance of the data was deter-
mined using the x2-test. A P value of ,0.05 was con-
sidered significant.
Results
The HFE genotypes for the patients with HH and nor-
mal subjects are summarized in Table 1. Of the
patients, 92.0% were homozygous and 4.5% were
heterozygous for the C282Y mutation. In three
patients, wild-type alleles were present. No person
homozygous for the C282Y mutation was found
amongst the control subjects.
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As can be seen in Fig. 2, heterozygous patients had
lower iron stores in general than homozygous
patients. Ten patients over 39 years old who were
homozygous for the C282Y mutation had 5 g or less
of iron stores. Of these, one patient was a blood
donor and one had ulcerative colitis.
As shown in Table 2, the C282Y mutation fre-
quency was higher in patients with HH than in con-
trol subjects. The frequency of H63D was higher in
the controls than in the patients with HH. However,
because the C282Y mutation is in complete linkage
disequilibrium with the H63D mutation, the only
chromosomes at risk of the H63D mutation are those
without the C282Y mutation. Thus, six of the 10
chromosomes at risk carried the H63D mutation,
giving a frequency of 60% in patients with HH as
compared with the controls where 29 of 225 chro-
mosomes at risk carried the H63D mutation giving a
frequency of 13% (P , 0.001). 
The clinical data of patients with normal alleles for
the C282Y are presented in Table 3. As can be seen
they all showed many features typical of haemochro-
matosis, both biochemical and clinical.
Discussion
The frequency of HH, which is a common genetic
disease, differs in various parts of Europe and the
Fig. 1 NuSieve gel electrophoresis of the polymerase chain reaction (PCR) fragments digested by enzyme restriction. (a) diagnosis of the
C282Y mutation; (b) diagnosis of the H63D mutation. Band sizes (in bp) are shown on the lateral sides; The molecular weight marker
(MWM) is the 100 bp ladder (Pharmacia Biotech, Sweden).
Table 1 Analysis of mutations in the HFE gene in 87 patients with
hereditary haemochromatosis and 117 normal subjects
Genotypes
Patientsa Controlsa
C282Y H63D (n 5 87) (n 5 117)
1/1 2/2 80 (92.0) 00
1/1 1/2 00 00
1/1 1/1 00 00
1/2 2/2 01 (1.1) 09 (7.7)
1/2 1/2 03 (3.4) 00
1/2 1/1 00 00
2/2 2/2 01 (1.1) 80 (68.4)
2/2 1/2 01 (1.1) 27 (23.1)
2/2 1/1 01 (1.1) 01 (0.8)
aNumber of subjects with the genotype. Parentheses denote
percentage.
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USA [10–14]. Reports from Sweden have also shown
variations in the prevalence of HH [15–20].
Two mutations in HFE have been described. The
C282Y variant disrupts the interaction of the HFE
chain with the b2-microglobulin and thereby elimi-
nates cell-surface presentation. The other mutation
(H63D) does not interfere with the expression of the
HFE protein on the cell surface [21]. The role of the
H63D mutation in HH is still unclear.
In controls, we found no homozygous persons for
the C282Y mutation, while 7.7% were heterozygous,
giving an allelic frequency of 3.8% for the C282Y
mutation. If this mutation was indeed alone respon-
sible for HH, the prevalence for HH would be 0.16%.
Our data correspond well with previously published
frequencies on the prevalence of HH in the
Stockholm area [19].
We found that C282Y mutation in approximately
94% of chromosomes from patients with HH, while
only approximately 4% of chromosomes from the
control population carried this mutation. It has 
been shown that the C282Y mutation of the HFE
gene is present in a high percentage of white HH
patients. However, the frequency varies between
groups from different countries [2–7]. In Australia,
the C282Y mutation was present in 100% of HH
patients [5]. In contrast, only 69% of chromosomes
from Italian patients with HH carried this mutation
[7]. Our study confirms that the C282Y mutation is
strongly associated with HH. One of the C282Y
negative subjects was homozygous for the H63D
Table 2 Mutation frequencies in the HFE gene in 87 patients with
hereditary haemochromatosis and in 117 normal subjects
Patientsa Controlsa
Mutation (n 5 174) (n 5 234) Pb
C282Y 164 (94.2) 09 (3.8) ,0.001
H63D 006 (3.4) 29 (12.4) ,0.01
aNumber of chromosomes with mutation. Parentheses denote
percentage.
bx2-test.
Table 3 Clinical data on three out of 87 patients who did not carry the C282Y mutation
Genotypes Serum Serum Liver Related
Patient Age ALTa Serum irona transferrin ferritina biopsy Removed Liver symptoms/
no. (years/sex) C282Y H63D (mkatal L21) (mmol mL21) saturationa (%) (mg L21) iron gradeb iron (g) histology relatives
1 33/F 2/2 2/2 0.36 40 89 0804 3 6.0 Fibrosis Arthritis
2 57/F 2/2 1/2 1.20 47 89 0746 3 3.6 Fibrosis Arthritis/
sibling
with HH
3 58/M 2/2 1/1 1.26 44 93 1410 3 6.1 Fibrosis Diabetes
aNormal values: alanine transaminase (ALT): males ,0.8 mkatal L21, females ,0.6 mkatal L21; serum iron: 11–32 mmol mL21; serum
transferrin saturation: 10–60%; serum ferritin: 9–210 mg L21.
bHepatic iron overload grading according to Scheuer et al. [8].
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Fig 2 Relationship between iron removed by phlebotomies and age
at diagnosis in males (a) and in females with hereditary
haemochromatosis (HH) (b). s, negative for C282Y mutation; j,
heterozygous for the mutation; m, homozygous patients. Patients
in whom phlebotomy treatment had not been terminated are not
represented. The arrows indicate heterozygosity for both C282Y
and H63D mutations.
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mutation. However, the importance of this homozy-
gosity is not known, as one of the control subjects
was also homozygous for this mutation. All patients
in Table 3 had several clinical findings strongly
indicating the diagnosis of HH, such as high
transferrin saturation, associated symptoms, and 
in one patient, affected relatives. The fact that 
there are patients who do not have any of these 
two mutations suggests that additional mutations
may be present either within the HLA region or 
on other, not yet detected, loci [2, 7]. In the 
present study we also found a similar frequency of
the HFE C282Y mutation in Sweden, as compared
with data from the USA, Australia and France, but 
a considerably higher frequency than that reported
from Italy [7]. This also indicates that other factors
than these mutations in the HFE gene may
contribute to the expression of the disease. Our
patients were all diagnosed with accepted criteria.
Treatment showed that many had rather low iron
levels. This has not been found in other studies. The
explanation of this difference is not evident. One
reason may be the often used health testing of
people without symptoms of disease in Sweden,
which recruits patients with only biochemical
alterations, and probably a mild expression of the
disease.
The role of the other mutation (H63D) in the phe-
notypic expression of HH is unclear. In controls, the
frequency of H63D mutation is higher than the
C282Y mutation. If the H63D mutation had a criti-
cal role in the development of HH, we would expect
to find more homozygous patients for this mutation.
However, amongst four patients heterozygous for the
C282Y mutation, three were also heterozygous for
the H63D mutation, compared with the controls
where none of the individuals heterozygous for the
C282Y mutation had the H63D mutation. This indi-
cates that either this mutation is in linkage disequi-
librium with other yet undiscovered mutations, or
that the H63D itself is a deleterious mutation, which
together with the C282Y mutation causes
haemochromatosis. Because we found that of the 10
chromosomes at risk in the patients, six (60%) had
the H63D mutation, this mutation may be important
for the expression of the HH.
The finding of one HH patient negative for both
mutations indicates that other not yet detected muta-
tions may also be responsible for the phenotypic
expression of the disease.
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